본문 바로가기
KERD
논문KCI 등재

Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?

조민현|Hee Sun Beak
대한소아신장학회 (The Korean Society Of Pediatric Nephrology)|2023.12|Childhood Kidney Diseases (Childhood Kidney diseases)|제27권 제2호|pp. 76-81|DOI 10.3339/ckd.23.021

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ChildPolycystic kidneyautosomal dominantTolvaptan
주제분류소아과학

초록

Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan is currently the preferred treatment of rapidly progressive disease ADPKD in adult patients; however, since cyst formation in ADPKD begins early in life, (frequently in utero), and significant disease progression with cyst expansion occurs in the first decade, tolvaptan may be advantageous as a preemptive treatment in children with ADPKD. Tolvaptan has already been used to successfully treat refractory edema or hyponatremia in children; this literature review provides insight into the biochemical basis of its action to contextualize its use in the pediatric population.

Abstract

Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan is currently the preferred treatment of rapidly progressive disease ADPKD in adult patients; however, since cyst formation in ADPKD begins early in life, (frequently in utero), and significant disease progression with cyst expansion occurs in the first decade, tolvaptan may be advantageous as a preemptive treatment in children with ADPKD. Tolvaptan has already been used to successfully treat refractory edema or hyponatremia in children; this literature review provides insight into the biochemical basis of its action to contextualize its use in the pediatric population.

참고문헌 (32)

  1. Olesen ET, "Aquaporin 2 regulation : implications for water balance and polycystic kidney diseases", Nat Rev Nephrol, 17, pp.765~781 (2021)
  2. Torres VE, "Role of vasopressin antagonists", Clin J Am Soc Nephrol, 3, pp.1212~1218 (2008)
  3. Torres VE, "Tolvaptan in patients with autosomal dominant polycystic kidney disease", N Engl J Med, 367, pp.2407~2418 (2012)
  4. Torres VE, "Tolvaptan in later-stage autosomal dominant polycystic kidney disease", N Engl J Med, 377, pp.1930~1942 (2017)
  5. Torres VE, "Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease", Clin J Am Soc Nephrol, 16, pp.48~58 (2020)
  6. Torres VE, "Tolvaptan in ADPKD patients with very low kidney function", Kidney Int Rep, 6, pp.2171~2178 (2021)
  7. Zhou X, "Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD", Kidney Int Rep, 7, pp.1037~1048 (2022)
  8. Chebib FT, "A practical guide for treatment of rapidly progressive ADPKD with tolvaptan", J Am Soc Nephrol, 29, pp.2458~2470 (2018)
  9. Muller RU, "An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International", Nephrol Dial Transplant, 37, pp.825~839 (2022)
  10. Gkekas E, "Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease(ADPKD)patients on tolvaptan", Front Nephrol, 2, pp.984165~ (2022)
  11. Kataoka H, "Public support for patients with intractable diseases in Japan : impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease", Clin Exp Nephrol, 27, pp.809~818 (2023)
  12. Gkika V, "The efficacy, the treatment response and the aquaretic effects of a three-year tolvaptan regimen in polycystic kidney disease patients", Clin Pract, 13, pp.1035~1042 (2023)
  13. Shimizu M, "Tolvaptan therapy for massive edema in a patient with nephrotic syndrome", Pediatr Nephrol, 29, pp.915~917 (2014)
  14. Marx-Berger D, "Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants", Acta Paediatr, 105, pp.e334~7 (2016)
  15. Higashi K, "Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH)", Int J Cardiol, 205, pp.37~42 (2016)
  16. Katayama Y, "Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery", Gen Thorac Cardiovasc Surg, 65, pp.622~626 (2017)
  17. Tuli G, "Tolvaptan treatment in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion : a report of three cases", J Clin Res Pediatr Endocrinol, 9, pp.288~292 (2017)
  18. Koksoy AY, "Tolvaptan use to treat SIADH in a child", J Pediatr Pharmacol Ther, 23, pp.494~498 (2018)
  19. Kerling A, "First experience with tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery", BMC Pediatr, 19, pp.57~ (2019)
  20. Delbet JD, "Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome", Pediatr Nephrol, 35, pp.1347~1350 (2020)
  21. Meena J, "Efficacy and safety of combination therapy with tolvaptan and furosemide in children with nephrotic syndrome and refractory edema : a prospective interventional study", Indian J Pediatr, 89, pp.699~705 (2022)
  22. Piffer A, "Vaptans for oedematous and hyponatraemic disorders in childhood : a systematic literature review", Br J Clin Pharmacol, 88, pp.4474~4480 (2022)
  23. Hartung EA, "Tolvaptan for autosomal dominant polycystic kidney disease in children : why, who, and when?", Clin J Am Soc Nephrol, 18, pp.11~13 (2023)
  24. Gimpel C, "The wind of change in the management of autosomal dominant polycystic kidney disease in childhood", Pediatr Nephrol, 37, pp.473~487 (2022)
  25. De Rechter S, "Is autosomal dominant polycystic kidney disease becoming a pediatric disorder?", Front Pediatr, 5, pp.272~ (2017)
  26. Alpers DH, "Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease(ADPKD) : an analysis of pivotal clinical trials", Am J Kidney Dis, 81, pp.281~293 (2023)
  27. Janssens P, "Expanding the role of vasopressin antagonism in polycystic kidney diseases: from adults to children?", Pediatr Nephrol, 33, pp.395~408 (2018)
  28. Gilbert RD, "Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease", Pediatr Nephrol, 32, pp.893~896 (2017)
  29. Raina R, "Autosomal-dominant polycystic kidney disease : tolvaptan use in adolescents and young adults with rapid progression", Pediatr Res, 89, pp.894~899 (2021)
  30. Schaefer F, "Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial", Eur J Pediatr, 178, pp.1013~1021 (2019)
  31. Mekahli D, "Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease : randomized controlled trial", Clin J Am Soc Nephrol, 18, pp.36~46 (2023)
  32. Gimpel C, "International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people", Nat Rev Nephrol, 15, pp.713~726 (2019)

관련 논문AI추천

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease한승엽, Yaerim Kim대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제3호Autosomal Dominant Polycystic Kidney Desease Coexisting with Renal Dysplasia. First Case Described and Followed Since Prenatal PeriodCarmen Truyols대한소아신장학회 · Childhood Kidney Diseases2018 · 제22권 제2호Current treatment of hereditary nephrogenic diabetes insipidus in childrenSuh Jin-Soon대한소아신장학회 · Childhood Kidney Diseases2025 · 제29권 제2호A Pediatric Case of AVPR2-related Nephrogenic Syndrome of Inappropriate Antidiuresis조민현, Eun Joo Lee, Hae Min Jang, Hee Sun Baek, Hyunwoo Bae대한소아신장학회 · Childhood Kidney Diseases2020 · 제24권 제2호Nonobstructive Bilateral Hydronephrosis & Hydroureter from Nephrogenic Diabetes Insipidus with a Novel Mutation of AQP2 Gene (p.A123G)남궁미경, Jeon Ihn Soo, Ki Sup Song대한소아신장학회 · Childhood Kidney Diseases2016 · 제20권 제2호Newly Detected PKHD1 Gene Mutation in a Newborn with Fatal Autosomal Recessive Polycystic Kidney DiseaseAi-Rhan Kim, Beom Hee Lee, Byoung Sop Lee, Chong Jai Kim, Gu Hwan Kim, Hyun-Jeong Do, Ki-Soo Kim, Seong-Hee Oh, Ye Jee Byun대한신생아학회 · Neonatal medicine2015 · 제22권 제4호

이 간행물의 다른 논문 (12건)

Introducing the general management of glomerular disease from a pediatric perspective based on the updated KDIGO guidelinesLim Seon Heepp. 55-63Comprehensive review of membranoproliferative glomerulonephritis: spotlighting the latest advances in revised classification and treatmentKim Jeong Yeonpp. 64-69An overview of Dent diseaseSeong Hwan Chang, Eun Mi Yangpp. 70-75Anemia in children with chronic kidney diseaseMin Ji Park, Min Hyun Chopp. 82-88Nutcracker syndrome in children: review of symptom, diagnosis, and treatmentDiana S. Kalantar, Se Jin Park, Jae Il Shinpp. 89-96
원문 보기